Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004125 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00004125 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group.
The verdict
NCT00004125, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of combination chemotherapy in treating women who have stage II or stage IIIA breast cancer that has spread to the lymph nodes.
Interventions
- DRUG cyclophosphamide
- DRUG docetaxel
- DRUG paclitaxel
- DRUG doxorubicin hydrochloride
- DRUG tamoxifen citrate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-11-16 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004125
The ClinicalTrials.gov registry entry for NCT00004125 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00004125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004125 about?
NCT00004125 is a clinical study titled "Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens o...
What is the current status of trial NCT00004125?
This trial is currently completed. It is a Phase 3 study. The study started on 1999-11-16. Estimated completion is 2016-11.
What interventions are being tested in trial NCT00004125?
The interventions under investigation include: cyclophosphamide (DRUG), docetaxel (DRUG), paclitaxel (DRUG), doxorubicin hydrochloride (DRUG), tamoxifen citrate (DRUG).
Who is sponsoring clinical trial NCT00004125?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.